Myeloma pathways to diagnosis UCLP audit

Similar documents
Things You Don t Want to Miss in Multiple Myeloma

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

Multiple Myeloma Patient s Booklet

Multiple Myeloma Workshop- Tandem 2014


UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO Gundersen Health System Center for Cancer and

Malignant Lymphomas and Plasma Cell Myeloma

FastTest. You ve read the book now test yourself

MULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology

Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines

Multiple Myeloma Understanding your diagnosis

A Clinical Primer. for Managed Care Stakeholders

Monoclonal Gammopathy of Undetermined Significance (MGUS) Facts

SOUTHWEST ONCOLOGY GROUP CLINICAL RESEARCH ASSOCIATE (CRA) MANUAL. MYELOMA CHAPTER 10 REVISED: March 2008

New diagnostic criteria for myeloma

Investigation of B cell malignancies. Dr. Joanna Sheldon Protein Reference Unit St. George s s Hospital

Plasma cell dyscrasias Mark Drayson

Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma.

Background Information Myeloma

Kharkov Regional Centre of Cardiovascular surgery V.N. Karazin Kharkov National University Department of Internal Medicine.

The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline

Stem Cell Transplantation

Multiple Myeloma. Abstract. Introduction

Appendix D- Monoclonal Gammopathy of Undetermined Significance (MGUS)

Multiple Myeloma. This reference summary will help you understand multiple myeloma and its treatment options.

Cleveland Clinic Taussig Cancer Institute s Multiple Myeloma Program

The Role of the Haematology Specialist Nurse. Catherine Chapman RN. BSc (Hons)

TABLE OF CONTENTS. Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data

What you need to know about. Multiple Myeloma. Based on a brochure from National Institutes of Health National Cancer Institute STDAVIDS.

It can be devastating to be diagnosed with a cancer like multiple myeloma. But there are treatments that can help you live longer and feel better.

A Focus on Multiple Myeloma

Whole Antibody and Free Light Chain Production by Plasma Cells

Radiotherapy in Plasmacytoma and Myeloma. David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015

A Diagnostic Chest XRay: Multiple Myeloma

Multiple Myeloma. Understanding your diagnosis

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital

Bupa By You. Summary

Waldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May Morie Gertz MD, MACP

Asymptomatic or smoldering myeloma with no symptoms and slow growing cancer cells

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

Radiotherapy in locally advanced & metastatic NSC lung cancer

Cancer services children s CSCF v3.2

Kidney Cancer OVERVIEW

Acute Oncology Service Patient Information Leaflet

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Bone Disease in Myeloma

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

Management of spinal cord compression

University College Hospital. Metastatic spinal cord compression (MSCC) information for patients at risk of developing MSCC.

Information Pathway. Myeloma tests and investigations. Paraprotein measurement

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment

Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for

.org. Metastatic Bone Disease. Description

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM

Myeloma. A guide for patients and families leukaemia.org.au

I've Just Been Diagnosed. with Multiple Myeloma, What s Next?

MULTIPLE MYELOMA. Overview

Acute Myeloid Leukemia

How To Get The Elite Health Insurance Plan

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)

Myeloma. A guide for patients, families and whanau

Multiple Myeloma with Pathologic Fracture: the Role and Treatment Consideration of RT

Improving access and reducing costs of care for overactive bladder through a multidisciplinary delivery model

Chapter 13. The hospital-based cancer registry

Understanding. Multiple Myeloma. Caring for people with cancer

Multiple Myeloma Making Sense of the Report Forms. Parameswaran Hari Medical College of Wisconsin Milwaukee

Outline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD

Underwriting Methods and Chronic Conditions. Everything you need to know about new, pre-existing and chronic conditions

Use of free light chain analysis in the diagnosis, prognosis and therapy of multiple myeloma. Amitabha Mazumder, MD

Cancer Rehab and Exercise for the Patient with Multiple Myeloma. Molly Megan MHS PT

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

Guidelines for the Operation of Burn Centers

MALIGNANT SPINAL CORD COMPRESSION. Kate Hamilton Head of Medical Oncology Ballarat Health Services

Cancer research in the Midland Region the prostate and bowel cancer projects

Business Loan Insurance Plan Critical Illness Claim - Policy 57903

Table of Contents Accelerate Your Research Introduction I. From the Real World to the Lab II. Research Challenges III. How Can Conversant Bio Help?

METASTASES TO THE BONE

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization N = 50

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN CANCER PATIENTS 1. Aim/Purpose of this Guideline

Bone Disease in Myeloma

Understanding Protein Electrophoresis

PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES.

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

PATIENT HANDBOOK. Multiple Myeloma. Improving Lives Finding the Cure. Cancer of the Bone Marrow. Prepared by Brian G.M. Durie, M.D.

REFERENCE CODE GDHCER PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA EPIDEMIOLOGY FORECAST TO 2023

Transcription:

Myeloma pathways to diagnosis UCLP audit Dr Neil Rabin Consultant Haematologist University College London Hospitals & North Middlesex University Hospital

Myeloma Clinical Features Bone pain (70%) High calcium levels Recurrent infections Pathological fractures Kidney dysfunction (70%) Bone marrow failure (anaemia) Hyperviscosity

Spectrum of Disease NO TREATMENT REQUIRED OBSERVATION ONLY Normal MGUS Asymptomatic myeloma TREATMENT REQUIRED Myeloma No bone lesions < 10% plasma cells No bone lesions > 10% plasma cells Related Organ or Tissue Impairment: HyperCalcemia Renal failure Anaemia Bone pain

Pathway to diagnosis Patients newly diagnosed with sympt. myeloma Feb to Aug 2014 Case note review UCLH Barts Health (not Whipps X or Newham sites) Patients were excluded if: Referred for salvage chemotherapy / transplant Asymptomatic / Smoldering myeloma / MGUS Amyloidosis (often diagnosed elsewhere and referred) Solitary plasmacytoma Referral pathway Healthcare professional seen previously (duration) Symptoms related to myeloma (duration) Myeloma staging / response to treatment / impact morbidity/response

Patient characteristics 36 patients identified (20 pts Barts Health, 16 pts UCLH) Median age at diagnosis = 65 years (range 37 to 90 yrs) Male = 20 pts, Female = 16 pts (ratio 1.2:1) Isotype IgG 14 (39%) IgA 12 (33%) Light Chain (BJP) 8 (22%) IgM 1 (3%) Non-secretor 1 (3%) International Staging System (ISS) 1 14 (39%) 2 5 (14%) 3 14 (39%) Unknown 3 (8%)

Patient characteristics 36 patients identified (20 pts Barts Health, 16 pts UCLH) Myeloma defining symptoms (CRAB criteria): Bone disease Anaemia Calcium Renal dysfunction Hyperviscosity 26 (72%) patients 20 (55%) patients 12 (33%) patients 13 (36%) patients 2 ( 5%) patients

Patient characteristics 36 patients identified (20 pts Barts Health, 16 pts UCLH 35 patients -chemotherapy 1 patient radiotherapy alone (declined chemotherapy) Response 29 (80%) patients responded (PR or better) 7 (20%) patients progressed 2 (5%) patients salvage treatment 5 (14%) patients died (myeloma related) Alive - 31(86%) patients Dead 5 (14%) patients

Referral pathway to haemato-oncologist 9 8 7 6 5 4 3 2 1 0 Primary care 2WW Primary care not 2WW Outpatient - 2WW Outpatient - not 2 WW Outpatient - MGUS/smMM Inpatient - A+E Inpatient - other team

Which healthcare professional did patient see before diagnosis made? 36 patients identified (20 pts Barts Health, 16 pts UCLH) 28 (78%) patients seen by GP / primary care (underestimate) 10 (28%) patients seen their GP at least on 2 occasions 16 (44%) patients seen in other clinics 5 (14%) haematology 4 (12%) surgical / orthopaedic 2 (5%) chest clinic 2 (5%) neurology 2 (5%) rheumatology 1 (3%) oncology 4 (11%) patients seen in A+E and discharged home Time interval from first contact to diagnosis, 1 to 8 months Median number of visits to healthcare professional = 3 (range 1 to 8)

Symptoms at diagnosis 25 20 15 10 5 0 Bone pain Pathological fracture Cord / nerve Anaemia Renal Calcium Infection

Symptom lead to referral 36 patients identified (20 pts Barts Health, 16 pts UCLH) Bone pain 25 (69%) Pathological fracture 11 (30%) Cord / nerve 7 (19%) Anaemia 18 (50%) Renal dysfunction 12 (33%) Hypercalcaemia 16 (44%) Infection 2 ( 5%) Duration of symptoms available (from notes) for 20 patients Median duration = 3 months (range 1 to 12 months)

Impact on morbidity and response to treatment 36 patients identified (20 pts Barts Health, 16 pts UCLH) Subjective assessment 15 (41%) patients delay in diagnosis had an impact on morbidity Bone disease Cord compression Pathological fracture Renal function 3 (8%) patients impacted on response to treatment On dialysis and difficult to deliver chemotherapy

Case history 47 year old man 6 month history of chest wall and back pain Seen by GP 3 occasions Referred by GP 2WW to chest clinic (?lung ca) CXR unremarkable Bloods clinic unremarkable CT requested from clinic lytic bone disease?follow up Admitted under general medics Bone pain, pathological fracture Hypercalcaemia Renal failure

Conclusion Patients identified in 2 large hospitals Need to include DGH Patients were seen on multiple occasions before diagnosis Median of 3 occasions by healthcare professional Commonly diagnosed as present via A+E 48 % pts diagnosed as an emergency presenting through A+E Despite previous contact with healthcare professional 2 WW (consultant upgrade) pathway underutilised 8 % pts referred using 2 week wait pathway Unusual to have referral from GP (11% referred from primary care) Patient seen in other OPD (surgical commonest) Follow up of patients with smoldering myeloma / MGUS allows early initiation of therapy 17% pts regular haematology f/u (prevented problems) Data not captured Referred for MGUS / sm. myeloma / other plasma cell disorders

THANK YOU Heather Oakervee (Barts Health) Data managers identifying patients